Prognostic markers in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1588-1589

  Delabie, Jan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN BCL 2; PROTEIN BCL 6; SURVIVIN;

AGE; CANCER STAGING; DISEASE MARKER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIGENS, CD40; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956321977     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.508191     Document Type: Note

References (10)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2008.
2. Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a neverending story. Ann Oncol 2010;21: 1486-1491.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
4. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109: 1857-1861.
5. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-1914.
6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
7. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
8. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25: 805-812.
9. Rydström K, Linderoth J, Nyman H, et al. CD40 is a potential marker of favorable prognosis in patients with diffuse large Bcell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2010;51:1643-1648.
10. Dupire S, Coiffier B. Targeted treatment and new agents in diffuse large B cell lymphoma. Int J Hematol. 2010 Jun 18. [Epub ahead of print].